New funding will support increasing enrollment in its ongoing first-in-human trial, EFEMORAL I LOS ALTOS, Calif., Dec. 13, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the closing of its $4.9M preferred Series A1 round. Supported by existing investors as well as an experienced cohort of new investors, the proceeds […]